Trastuzumab Deruxtecan for <i>ERBB2</i> -Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases
In this secondary analysis, T-DXd at the approved dose of 5.4 mg/kg showed antitumor activity in patients with previously treated ERBB2-mutant metastatic NSCLC with or without brain metastases. This finding supports T-DXd 5.4 mg/kg use in this population.
Authors
- Maha Karnoub
- Kaline Pereira
- Junichi Shimizu (ORCID: https://orcid.org/0000-0003-1204-1371)
- Toshio Kubo
- Kiichiro Ninomiya (ORCID: https://orcid.org/0000-0002-2134-2865)
- Egbert F. Smit (ORCID: https://orcid.org/0000-0002-7329-6995)
- David Planchard (ORCID: https://orcid.org/0000-0002-1565-8310)
- Ahmed Ali (ORCID: https://orcid.org/0000-0003-2157-4399)
- Yasushi Goto (ORCID: https://orcid.org/0000-0002-7437-5054)
- Rie Yonemochi
- Ayumi Taguchi (ORCID: https://orcid.org/0000-0002-5491-3871)
- Kōichi Goto (ORCID: https://orcid.org/0000-0002-3023-2510)
- Hidetoshi Hayashi (ORCID: https://orcid.org/0000-0001-8787-5587)
- Bob T. Li (ORCID: https://orcid.org/0000-0001-6661-8733)
- M. Pérol
- Pasi Antero Janne (ORCID: https://orcid.org/0000-0002-7821-4928)
- Adrianus J. de Langen (ORCID: https://orcid.org/0000-0001-7343-633X)
- Misako Nagasaka (ORCID: https://orcid.org/0000-0001-5308-615X)
- David Leung (ORCID: https://orcid.org/0000-0002-2078-7934)
- Enriqueta Felip (ORCID: https://orcid.org/0000-0002-7620-0098)
- Kazuhiko Nakagawa
Institutions
- Hebron University (PS)
- Memorial Sloan Kettering Cancer Center (US)
- Daiichi Sankyo (Germany) (DE)
- University of California, Irvine (US)
- Leiden University Medical Center (NL)
- Institut Gustave Roussy (FR)
- The Netherlands Cancer Institute (NL)
- University of California, Irvine Medical Center (US)
- Okayama University Hospital (JP)
- Daiichi-Sankyo (Japan) (JP)
- Centre Léon Bérard (FR)
- AstraZeneca (France) (FR)
- Dana-Farber Cancer Institute (US)
- Aichi Cancer Center (JP)
- AstraZeneca (Poland) (PL)
- National Cancer Center Hospital East (JP)
- Daiichi Sankyo (United States) (US)
- Kindai University (JP)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.43107
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Memorial Sloan-Kettering Cancer Center
- Revolution Medicines
- Genentech
- Daiichi Sankyo Europe